Plexāā, a startup known for its BLOOM43 medical device for breast surgery, has announced the completion of a $4.5 million funding extension. Plexāā has been backed by TCP Health Ventures (the dedicated healthcare investment arm of The Capital Partnership group of companies), which led the Seed Round.
This extension round comprises existing and new investors, including TCP. Further investment includes over $1.6 million in i4i grant funding from the National Institute for Health and Care Research (NIHR), and $1.3 million from Thena Capital, a London-based VC firm backed by the British Business Bank and focused on digital health and fast-tracked Medtech.
Complication rates in breast surgeries, such as infection, skin necrosis, and the need for additional procedures, can reach as high as 30%. BLOOM43 is the world’s first fully wearable medical device designed to help patients prepare for breast cancer surgery and reconstruction by utilizing Supraphysiological Preconditioning. This innovative technique safely and intermittently applies thermal preconditioning to the skin, triggering the release of heat-shock proteins that promote vasodilation and enhance blood flow to the area. Clinical trials have demonstrated that this process can reduce the risk of wound healing complications.
Along with its BLOOM43 companion app, the device has demonstrated substantial improvements in patient experience and surgical readiness, leveraging the power of holistic Prehabilitation and preconditioning. The company has already secured multiple partners for its upcoming U.S. commercial launch.
How the funding will be used: This strategic investment will fund the upcoming U.S. launch of BLOOM43 and support future innovations. Additionally, the funding strengthens the company’s position as they prepare for their Series A fundraising round.
Plexāā plans to collaborate with clinicians, patients, and partners worldwide to make prehabilitation and preconditioning the standard of care for surgery — and to deliver transformative solutions that address unmet needs in surgical care.
KEY QUOTES:
“I want to thank our team for the tremendous progress it has made to make this financing possible. Securing this funding validates confidence in our flagship technology and the concept of Supraphysiological Preconditioning™, and it energizes the team as we prepare to bring BLOOM43 to a wider patient population in the U.S. and beyond. The funds will support this pivotal launch and market expansion, as well as the exciting development of our technology platform – including devices and apps targeting additional surgical specialties and creating a whole new category in surgery.”
Dr. Saahil Mehta, founder and CEO of Plexāā
“Since 2023, we’ve been closely tracking Plexāā’s progress and the development of its first device, BLOOM43. We couldn’t be more excited for Plexāā to become our first portfolio company for THENA Capital’s Fund I. The company is solving a critical and under-addressed challenge across the surgical pathway- reducing post-operative complications for patients which also addresses the impact to both providers and payers.”
“Saahil and his team bring together clinical, engineering, and operational expertise from some of the UK’s leading institutions. Their bold ambition to scale globally, beginning with an imminent commercial launch in the U.S., is exactly the kind of UK MedTech leadership team we look to champion. Our fund’s commercialisation support model is well-suited to help Plexāā expand into women’s health and adjacent categories where better outcomes and patient experiences are urgently needed.”
Tatum Getty, founding General Partner at THENA Capital
